Resultados globales: 3 registros encontrados en 0.03 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
10 p, 1016.0 KB Global cancer control : responding to the growing burden, rising costs and inequalities in access / Prager, Gerald W (Medical University of Vienna) ; Braga, Sofia (Instituto CUF Oncologia) ; Bystricky, Branislav (Faculty Hospital Trencin) ; Qvortrup, Camilla (Odense University Hospital. Department of Oncology) ; Criscitiello, Carmen (Istituto Europeo di Oncologia) ; Esin, Ece (Ankara Oncology Education and Research Hospital) ; Sonke, Gabe S (Netherlands Cancer Institute) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ; Karamouzis, Michalis (National and Kapodistrian University of Athens) ; Strijbos, Michiel (AZ KLINA Hospitals) ; Yazici, Ozan (Ankara Numune Education and Research Hospital) ; Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ; Banerjee, Susana (Royal Marsden Hospital NHS Foundation Trust) ; Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ; Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ; Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona.Departament de Medicina) ; Zielinski, Christoph C (Medical University Vienna, General Hospital, and Vienna Cancer Center) ; Casali, Paolo G (Istituto Nazionale Tumori) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Jezdic, Svetlana (European Society for Medical Oncology) ; McGregor, Keith (European Society for Medical Oncology) ; Bricalli, Gracemarie (European Society for Medical Oncology) ; Vyas, Malvika (European Society for Medical Oncology) ; Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70. [...]
2018 - 10.1136/esmoopen-2017-000285
ESMO Open, Vol. 3 (february 2018)  
2.
10 p, 506.2 KB Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights / Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Élez Fernández, Mª Elena (Universitat Autònoma de Barcelona. Hospital Universitari de la Vall d'Hebron) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ; Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Capdevila, Jaume (Vall d'Hebron Institut d'Oncologia) ; Alsina Maqueda, Maria (Vall d'Hebron Institut d'Oncologia) ; Sauri, Tamara (Vall d'Hebron Institut d'Oncologia) ; Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ; Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ; Ruiz‐Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ; Landolfi, Stefania (Universitat Autònoma de Barcelona) ; Palmer, Hector G. (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272  
3.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, A. (Universitat de València) ; Grávalos, Cristina (Hospital Universitario Doce de Octubre) ; Pericay, Carles (Corporació Sanitària Parc Taulí) ; Gil Calle, S. (Hospital Carlos Haya) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío) ; García Carbonero, Rocio (Hospital Universitario Doce de Octubre) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.